<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Case definition and classification criteria for congenital rubella syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Case definition and classification criteria for congenital rubella syndrome</h1>
<div class="graphic"><div class="figure"><div class="ttl">Case definition and classification criteria for congenital rubella syndrome</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup width="80%"></colgroup> <tbody> <tr> <td class="subtitle1_left">Category</td> <td class="subtitle1_left">Definition</td> </tr> <tr> <td><strong>Suspected</strong></td> <td>An infant who does not meet the criteria for a probable or confirmed case (as defined below) but who has ≥1 of the following <strong>clinical findings of CRS</strong>: <ul class="decimal_heading"> <li>Cataracts</li> <li>Congenital glaucoma</li> <li>Congenital heart disease (most commonly PDA or PPS)</li> <li>Hearing loss</li> <li>Pigmentary retinopathy</li> <li>Purpura</li> <li>Hepatosplenomegaly</li> <li>Jaundice</li> <li>Microcephaly</li> <li>Developmental delay</li> <li>Meningoencephalitis</li> <li>Radiolucent bone disease</li> </ul> </td> </tr> <tr> <td rowspan="4"><strong>Probable</strong></td> <td><strong>Either</strong></td> </tr> <tr> <td>An infant who does not have laboratory evidence of CRI (as defined below) but has ≥2 of the following clinical findings, without a more plausible etiology: <ul class="decimal_heading"> <li>Cataracts or congenital glaucoma*</li> <li>Congenital heart disease (most commonly PDA or PPS)</li> <li>Hearing loss</li> <li>Pigmentary retinopathy</li> </ul> </td> </tr> <tr> <td><strong>OR</strong></td> </tr> <tr> <td>An infant who does not have laboratory evidence of CRI (as defined below) but has ≥1 of the following clinical findings, without a more plausible etiology: <ul class="decimal_heading"> <li>Cataracts or congenital glaucoma*</li> <li>Congenital heart disease (most commonly PDA or PPS)</li> <li>Hearing loss</li> <li>Pigmentary retinopathy</li> </ul> <p class="extra_spacing_top"><strong>Plus</strong> ≥1 of the following clinical findings:</p> <ul class="decimal_heading"> <li>Purpura</li> <li>Hepatosplenomegaly</li> <li>Microcephaly</li> <li>Developmental delay</li> <li>Meningoencephalitis</li> <li>Radiolucent bone disease</li> </ul> </td> </tr> <tr> <td><strong>Confirmed</strong></td> <td>An infant with both: <ul class="decimal_heading"> <li><strong>Clinical findings of CRS</strong> (≥1 of the findings listed above)</li> </ul> <p class="extra_spacing_top"><strong>Plus</strong></p> <ul class="decimal_heading"> <li><strong>Laboratory evidence of CRI</strong>, as demonstrated by <strong>any</strong> of the following: <ul> <li>Isolation of rubella virus</li> <li>Detection of rubella-specific IgM in the infant</li> <li>Rubella IgG titer in the infant that persist at a higher level and for a longer time than expected from transfer of maternal antibody (ie, rubella IgG titer that does not drop at the expected rate of a 2-fold decline per month)<sup>¶</sup></li> <li>Positive PCR for rubella virus</li> </ul> </li> </ul> </td> </tr> <tr> <td><strong>Infection only</strong></td> <td>An infant without any clinical findings of CRS (listed above) but with laboratory evidence of CRI (as defined above)<sup>Δ</sup></td> </tr> </tbody></table></div><div class="graphic_lgnd">This table summarizes the criteria used to define and classify CRS and CRI based upon clinical and laboratory findings. These definitions were approved by the Council of State and Territorial Epidemiologists (CSTE) in 2009 and were adopted by the CDC in 2010. They continue to be the definitions used in the United States and many other regions.</div><div class="graphic_footnotes"><p>CRS: congenital rubella syndrome; PDA: patent ductus arteriosus; PPS: peripheral pulmonary artery stenosis; CRI: congenital rubella infection; IgM: immunoglobulin M; IgG: immunoglobulin G; PCR: polymerase chain reaction; CDC: Centers for Disease Control and Prevention.</p>
<p>* In probable cases, if the infant has both eye-related findings (cataracts and congenital glaucoma), they should be considered as a single finding.</p>
<p>¶ Infants with clinical findings of CRS who test negative soon after birth should be retested later in infancy. Approximately 20% of infected infants tested for rubella IgM may not have detectable titers before age one month.</p>
Δ In cases classified as infection only, if any compatible clinical finding (eg, hearing loss) is identified later, the case is reclassified as confirmed.</div><div class="graphic_reference">Adapted from: Lanzieri T, Redd S, Abernathy E, Icenogle J. Congenital rubella syndrome. In: Manual for the Surveillance of Vaccine-Preventable Diseases, Roush SW, Baldy LM, Hall MAK (Eds), National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention 2020. <a href="https://www.cdc.gov/vaccines/pubs/surv-manual/chpt15-crs.html" target="_blank">https://www.cdc.gov/vaccines/pubs/surv-manual/chpt15-crs.html</a> (Accessed on May 10, 2023).</div><div id="graphicVersion">Graphic 55913 Version 9.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
